Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Director Acquires $249,745.83 in Stock

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Director Angie You bought 26,597 shares of the business’s stock in a transaction on Friday, June 20th. The shares were bought at an average price of $9.39 per share, for a total transaction of $249,745.83. Following the completion of the acquisition, the director now owns 26,597 shares of the company’s stock, valued at approximately $249,745.83. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.

Angie You also recently made the following trade(s):

• On Monday, June 23rd, Angie You purchased 1,403 shares of Oric Pharmaceuticals stock. The stock was acquired at an average cost of $9.43 per share, for a total transaction of $13,230.29.

Oric Pharmaceuticals Stock Down 2.5%

ORIC stock opened at $10.23 on Thursday. Oric Pharmaceuticals, Inc. has a twelve month low of $3.90 and a twelve month high of $14.67. The company has a market cap of $871.80 million, a PE ratio of -5.47 and a beta of 1.49. The business’s 50-day simple moving average is $6.93 and its 200 day simple moving average is $7.70.

Oric Pharmaceuticals (NASDAQ:ORIC) last released its earnings results on Monday, May 5th. The company reported ($0.42) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.09. On average, equities research analysts anticipate that Oric Pharmaceuticals, Inc. will post -2.17 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on ORIC. JPMorgan Chase & Co. raised their price target on Oric Pharmaceuticals from $21.00 to $22.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 price target on shares of Oric Pharmaceuticals in a research report on Monday, May 5th. Oppenheimer lowered their price target on Oric Pharmaceuticals from $15.00 to $12.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 6th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Oric Pharmaceuticals in a research report on Tuesday, May 6th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $20.00 price target on shares of Oric Pharmaceuticals in a research report on Monday. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $19.17.

Institutional Investors Weigh In On Oric Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. Rhumbline Advisers lifted its stake in Oric Pharmaceuticals by 4.6% during the fourth quarter. Rhumbline Advisers now owns 93,319 shares of the company’s stock worth $753,000 after purchasing an additional 4,072 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in Oric Pharmaceuticals by 1.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 417,955 shares of the company’s stock worth $3,373,000 after purchasing an additional 7,726 shares during the period. M&T Bank Corp lifted its stake in Oric Pharmaceuticals by 16.6% during the fourth quarter. M&T Bank Corp now owns 99,234 shares of the company’s stock worth $801,000 after purchasing an additional 14,097 shares during the period. PNC Financial Services Group Inc. lifted its stake in Oric Pharmaceuticals by 22.9% during the fourth quarter. PNC Financial Services Group Inc. now owns 13,517 shares of the company’s stock worth $109,000 after purchasing an additional 2,520 shares during the period. Finally, AlphaQuest LLC lifted its stake in Oric Pharmaceuticals by 2,597.8% during the fourth quarter. AlphaQuest LLC now owns 28,435 shares of the company’s stock worth $229,000 after purchasing an additional 27,381 shares during the period. 95.05% of the stock is owned by institutional investors and hedge funds.

About Oric Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.